Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Bayer, Kumquat Biosciences ink pact to develop, commercialize KRAS G12D inhibitor

Biological E, Takeda join hands to accelerate access to Dengue Vaccine in endemic areas

Ruchika Sharma29 Feb 2024 3:00 PM IST

Hyderabad: Takeda and Biological E. Limited (BE), an India-based Vaccines and Pharmaceutical Company, has announced a strategic partnership...

Bayer gets UK nod for Lynkuet for moderate to severe vasomotor symptoms associated with menopause

Bayer gets USFDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations

Ruchika Sharma29 Feb 2024 1:30 PM IST

BAY 2927088 was derived from Bayer's long-standing strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA.

Eli Lilly reports strong response for Mounjaro in India

Eli Lilly expects to launch diabetes drug Mounjaro in India next year: CEO

Ruchika Sharma29 Feb 2024 12:30 PM IST

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions.

USFDA concludes inspection at Zydus Lifesciences SEZ II, Ahmedabad plant

Alkem Labs gets USFDA EIR for Mandva facility

Ruchika Sharma29 Feb 2024 11:54 AM IST

Mumbai: Alkem Labs has announced that US Food and Drug Administration (US FDA) has issued an Establishment Inspection Report (EIR) for the...

Insufficient Efficacy, Safety Data: CDSCO Panel Rejects Zydus Phase III CT Waiver Request for Voclosporin

Zydus Lifesciences aims to launch first new drug in US by early 2026

Ruchika Sharma28 Feb 2024 4:30 PM IST

Ahmedabad: India's Zydus Lifesciences is aiming to launch its first new drug in the United States by early 2026, looking to tap into the...

AbbVie seeks USFDA nod for combination regimen of Venclexta, Acalabrutinib

USFDA set to increase inspections at Indian drug manufacturing units

Ruchika Sharma28 Feb 2024 3:30 PM IST

FDA Country Director (India) said the Indian pharma industry needs to invest more in automation for better compliance.

Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan for previously treated Advanced EGFR Mutated Non Small Cell Lung Cancer

Bristol Myers Squibb opens new USD 100 million facility in Hyderabad

Ruchika Sharma28 Feb 2024 1:30 PM IST

Hyderabad: Bristol Myers Squibb, one of the world's largest biopharmaceutical companies, has announced the opening of a new facility in...

Cadila Pharmaceuticals unveils aqueous Vitamin D injection

Ruchika Sharma28 Feb 2024 12:40 PM IST

This breakthrough not only enhances the efficacy of treatment but also ensures a painless and easy administration process, marking a significant...

DPIIT collaborate with Pfizer to strengthen India healthcare innovation ecosystem

Pfizer, NIPER Ahmedabad join hands to support healthcare innovation in India

Ruchika Sharma28 Feb 2024 11:38 AM IST

New Delhi: Pfizer has announced a collaboration with the National Institute of Pharmaceutical Education & Research (NIPER), Ahmedabad to...

CDSCO Panel Approves GSKs Proposal to Double Indian Patient Pool in Dostarlimab Trial

GSK posts positive headline results from phase III trial for Gepotidacin in uncomplicated urogenital gonorrhoea

Ruchika Sharma27 Feb 2024 2:30 PM IST

GSK plc has announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic...

Novartis to buy Tourmaline Bio for USD 1.4 billion

Bristol Myers Squibb concludes acquisition of RayzeBio

Ruchika Sharma27 Feb 2024 1:30 PM IST

Princeton: Bristol Myers Squibb has announced that it has successfully completed its acquisition of RayzeBio, Inc. With the completion of the...

Gilead Sciences gets USFDA nod for new Biktarvy indication

Expanded Indication for Gilead Biktarvy for HIV with suppressed viral loads, pre-existing resistance gets USFDA okay

Ruchika Sharma27 Feb 2024 12:30 PM IST

Foster City: Gilead Sciences, Inc. has announced the U.S. Food and Drug Administration (FDA) has approved a new, expanded indication for Biktarvy...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok